Alruwaili, H., Dehestani, B., & Roux, C. W. L. (2021). Clinical Impact of Liraglutide as a Treatment of Obesity. Clinical Pharmacology, Volume 13, 53–60. https://doi.org/10.2147/cpaa.s276085
Ard, J., Fitch, A., Fruh, S., & Herman, L. (2021). Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Advances in Therapy, 38(6), 2821–2839. https://doi.org/10.1007/s12325-021-01710-0
Compounding and the FDA: Questions and Answers. (2022, June 29). U.S. Food And Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. (2021, June 4). U.S. Food And Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
FDA Approves New Medication for Chronic Weight Management. (2023, November 8). U.S. Food And Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
FDA Drug Shortages. (2022, March 31). FDA. Retrieved July 12, 2024, from https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=c
FDA Group. (2024, June 18). 503A vs. 503B: A Quick-Guide to Compounding Pharmacy Designations & Regulations. https://www.thefdagroup.com/blog/503a-vs-503b-compounding-pharmacies
Generic Drugs: Questions & Answers. (2021, March 16). U.S. Food And Drug Administration. https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/generic-drugs-questions-answers
Generic Xenical Availability. (n.d.). Drugs.com. https://www.drugs.com/availability/generic-xenical.html
Guerciolini, R. (1997). Mode of action of orlistat. International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity, 21(Suppl 3), S12–S23. https://pubmed.ncbi.nlm.nih.gov/9225172/
How Ozempic Became a Celebrity Weight Loss Sensation. (2022, November 7). DiaTribe. https://diatribe.org/diabetes-medications/how-ozempic-became-celebrity-weight-loss-sensation
Lonneman, D. J., Jr, Rey, J. A., & McKee, B. D. (2013, August 1). Phentermine/Topiramate Extended-Release Capsules (Qsymia) for Weight Loss. PubMed Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814438/
National Institute of Diabetes and Digestive and Kidney Diseases. (2024, July 10). Prescription Medications to Treat Overweight & Obesity. National Institute of Health. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
Novo Nordisk Inc. (2014, December 24). Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management. PR Newswire. https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-for-saxenda-liraglutide-rdna-origin-injection-for-chronic-weight-management-300013975.html
Pan, X., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., Grandhi, G. R., Dimitriadis, G. K., Foo, R., Chew, N. W. S., Roux, C. W. L., Mamas, M. A., & Chan, M. Y. (2024). Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis. Obesity. https://doi.org/10.1002/oby.24002
Tan, X., Cao, X., Zhou, M., Zou, P., & Hu, J. (2017). Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs, 26(9), 1083–1089. https://doi.org/10.1080/13543784.2017.1360274
Teva Pharmaceutical Industries Limited. (2024, June 24). Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2024/Teva-Announces-Launch-of-Authorized-Generic-of-Victoza-liraglutide-injection-1.8mg-in-the-United-States/default.aspx
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., Ahmad, N. N., & Forrester, T. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine, 29(11), 2909–2918. https://doi.org/10.1038/s41591-023-02597-w
Williams, D. M., Nawaz, A., & Evans, M. (2020). Drug Therapy in Obesity: A Review of Current and Emerging Treatments. Diabetes Therapy, 11(6), 1199–1216. https://doi.org/10.1007/s13300-020-00816-y
Yerevanian, A., & Soukas, A. A. (2019). Metformin: Mechanisms in Human Obesity and Weight Loss. Current Obesity Reports, 8(2), 156–164. https://doi.org/10.1007/s13679-019-00335-3